Health News
One Rx Better Than Another For Melanoma?
Two medications are approved in the US to treat advanced melanoma. Zelboraf ( vemurafenib ) was approved in September, 2012. DTIC-Dome ( dacarbazine ) is used to treat Hodgkin's lymphoma as well as melanoma. Which is the better medication?
The Wild Card in Lymphoma
Cancer in one person can behave very differently than it might in another person. That’s because each person’s genes are unique. So some new cancer treatments can target the individual’s unique genetic fingerprint. Scientists are exploring possible new targets in lymphoma.
Rx Shortages Affecting Kids With Cancer
There has been a shortage of certain medications for about three years now. Particularly hard hit have been generic injectable drugs. The shortage of one medication has affected kids with cancer.
At the Heart of Genetic Shenanigans
There has been lots of really good news about a rare blood cancer. Several new drugs have been approved to treat all stages of chronic myeloid leukemia ( CML ). There’s also work happening to go after the disease at deeper levels.
Experimental Blood Cancer Rx is Showing Positive Results
There is excellent news for people with mantle cell lymphoma, a rare blood cancer. An experimental drug is demonstrating impressive results in a phase II clinical trial. But this is a limited research study, and the product is not yet available.
Cancer Wounds WTC Workers
When the World Trade Centers evaporated on 9/11, clouds of toxic chemicals were left in their wake. Researchers wanted to know the impact of these clouds on the health of rescue workers.
Bad to the Blood
When blood has gone bad, patients turn normally to donors for help. But using undefined stem cells from other parts of the patient's body may help donors become more of a last-minute option in the future.
New Leukemia Rx Hits Market
Folks living with two types of blood cancer have new choices as of today. The US Food and Drug Administration has approved Iclusig ( ponatinib ) to treat chronic myeloid leukemia ( CML ) and Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph + ALL).
FDA approves Iclusig to treat two rare types of leukemia
The US Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.
On The Job With Multiple Myeloma
Exposure to certain chemicals is thought to be a possible cause of a blood cancer called multiple myeloma. Researchers have honed in on this to see how occupation can affect risks.